Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InxMed FAK Inhibitor Ifebemtinib Gets Breakthrough Therapy Status for KRAS NSCLC
Details : IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib (KRAS G12C mutation inhibitor), for the first-line treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC
Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Previously-treated Solid Tumors
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2022
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable